Tempus AI, Inc. (TEM)
Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026?
TEM eyes 2026 growth by scaling diagnostics, MRD testing and AI-driven clinical apps as revenues surge 83%, though valuation concerns temper the outlook.
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth?
Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities.
Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI NASDAQ: TEM have gone on a wild rollercoaster ride. The firm's initial public offering price was $37.
TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.
Tempus AI: Buy The Post-Earnings Dip
Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention reached 126%, signaling strong customer value and recurring demand. Adjusted EBITDA turned positive in Q4, and 2026 guidance projects $65M adjusted EBITDA, though revenue growth is expected to slow to 25%.
Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
Tempus AI NASDAQ: TEM appears to be a smart buy for tech traders as it is a leading provider of AI-enabled services and infrastructure for healthcare, and its stock is set up to rebound robustly. Trading near 52-week lows in late February, the stock is more than 45% below the analysts' consensus, with tailwinds to drive it there.
Tempus AI: No AI Interruption Detected
Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth. The AI precision medicine company delivered 33% organic growth with Diagnostics revenue expanding due to higher test ASPs. Concerns over AI replacement have pressured the stock, yet TEM's proprietary data and hospital network provide defensible moats.
TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market
Tempus AI posts Q4 revenue beat with 83% surge, but wider-than-expected loss and operating shortfall send shares down in after-hours trading.
Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Tempus AI (TEM) Reports Q4 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.18 per share a year ago.
Live Earnings: Will Tempus AI Surprise Wall Street Tonight?
We are updating this story in real time as new information breaks. Stay on this page for the latest developments, key quotes, numbers, and market reaction as they happen.
